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Abstract Cachexia, and particularly the loss of metaboli-
cally active lean tissue, leads to increased morbidity and
mortality in affected patients. An impairment of strength
and functional status is usually associated with cachexia. A
variety of anabolic and appetite-stimulating agents have
been studied in patients with cachexia caused by various
underlying diseases. Overall, these studies have demon-
strated that treatment can increase body weight and/or lean
body mass. However, these therapies may have severe side
effects, particularly when utilizing testosterone and related
anabolic steroids targeting the androgen receptor. These
side effects include cardiovascular problems, prostate
hyperplasia and cancer in men, as well as virilization in
women.
Cachexia is defined as a multidimensional syndrome includ-
ing ongoing loss of skeletal muscle mass that withstands full
reversion by conventional nutritional support leading to
progressive functional impairment [1]. The development of
cachexia goes through various stages, that is pre-cachexia to
cachexia to refractory cachexia and can develop due to many
various diseases including cancer, heart and lung diseases, or
other diseases ([2–4] for excellent overviews). In the past,
many drugs were developed with anabolic properties with
the intention to “cure” cachectic states but many had limited
success and broad unwanted side effects. For instance, the
armada of anti-cachectic drugs includes appetite stimulants,
androgens, and growth factors (see Table 1). Mechanistically,
androgen receptor modulators were of particular interest.
Testosterone is converted in peripheral tissues by the enzyme
5[alpha]-reductase to 5[alpha]-dihydrotestosterone (DHT).
Both testosterone and DHT are able to activate the androgen
receptor resulting in an array of anabolic effects on the whole
body including heart, liver, bone, and skeletal muscle [5, 6].
Of concern are the increased risks for prostate hyperplasia
and cancer in men, virilization in women, and cardiovascular
side effects such as cardiac hypertrophy and atherosclerosis.
Therefore, nonsteroidal selective androgen receptor modu-
lators (SARMs) have been developed with preferential
effects on muscle and bone, and less side effects [7].
In the current issue of the Journal of Cachexia, Sarcopenia
and Muscle, Dalton and colleagues report a 12-week
randomized, double-blind, placebo-controlled multicenter
trial, where effects of GTx-024 (enobosarm), an orally
available nonsteroidal SARM with tissue-selective anabolic
activity have been tested in 120 healthy elderly men [8]. GTx-
024 treatment significantly increased total lean body mass and
improved physical function as well as insulin resistance. No
increased adverse effects were observed when compared to
placebo treatment. This is an exciting trial with numerous
implications for future cachexia treatment strategies.
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the significant dose-dependent increase in lean body mass
and loss of free fat. The increase in muscle mass and
decrease in fat may be one explanation for the observed
increase in physical strength in GTx-024-treated individu-
als. The reason why here no dose-dependent effect was
seen and only the highest dose (3.0 mg) resulted in
significant improvements is not clear, and although the
used stair climb power test is useful as a general test for
muscle strength, effects on physical activity needs to be
measured with broader techniques. In addition, spiroergo-
metric assessment of physical endurance would be helpful
to assess GTx-024 effects on endurance.
Several other issues in the current study are worthy to
note and to be considered in future trials with this
compound. With respect to the patient characteristics, it is
not clear why the body mass index (BMI) of the placebo
and 0.1, 0.3, and 1.0 mg dose groups was between 24 and
26 kg/m², whereas that of the 3.0 mg dose group, it was
considerably less (21.35 kg/m²). As significant improve-
ments, especially for %change in lean body mass and
physical activity were only found in the highest 3.0 mg
dose group, the differences in baseline BMI may partially
contribute to those effects, and therefore, future trials need
to balance baseline BMI more carefully.
The effects of GTx-024 on decreased blood glucose and
insulin resistance are remarkable and may be beneficial in
cachectic patients and diabetes. On the other hand, great
care is needed when this drug is co-administered with anti-
diabetic drugs including oral anti-diabetics and insulin with
respect to glucose control.
Although the overall cholesterol/HDL ratio was basically
unaffected by GTx-024, the general HDL decrease is still of
some concern as this is a proof that there are still
(unwanted) side (and not tissue-selective) effects of this
novel non-steroidal selective androgen modulator. Like-
wise, the increase in overall hemoglobin levels should not
be overseen. This may be beneficial in cachectic patients as
most suffer from anemia, but the underlying reasons should
be further investigated.
Currently, we still wait for clinically accepted and
approved therapies for the prevention of and treatment of
muscle wasting. This relatively large multicenter clinical
trial may be a major breakthrough although still questions
about tissue selectivity, side effects, and long-term safety
are unanswered. We also do not know whether the effects in
healthy elderly men will be seen in the wanted target
populations of cachectic patients due to alterations in liver
metabolism, kidney function, and so on. However, this
compound seems to be a significant milestone in SARM
development and, thus, a strong candidate for further
clinical studies.
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